PDF(Pubmed)
Abstract：
UNASSIGNED: This observational trial was performed to evaluate liver parameters in overweight or obese subjects in the context of insulin resistance and glucose control over time.
UNASSIGNED: Insulin resistance, glucose control and several parameters for liver integrity were monitored in 177 overweight (BMI > 28 kg/m2) subjects over a mean of 30 months. Volunteers were categorized according to insulin resistance (HOMAIR score) and glucose control in subjects with normal glucose control (NGT), impaired glucose control (IGT), or diabetes mellitus type 2 (T2DM). Liver fat and fibrosis were evaluated by sonographic elastography (FibroScan®) and clinical scores, such as the AST/ALT ratio, fatty liver index (FLI), and NAFLD fibrosis score (NFS).
UNASSIGNED: Liver fat fraction as estimated by the controlled attenuation parameter (CAP), and the FLI were significantly higher in subjects with T2DM compared to IGT and NGT. While fasting insulin levels and the HOMAIR score continuously increased over time, no change in CAP or FLI occurred during follow up. CAP was correlated with FLI (r = 0.50; p < 0.0001) and the HOMAIR score (r = 0.32; p < 0.0001). An inverse correlation was observed between serum adiponectin levels and FLI (r = -0.37; p < 0.0001), the HOMAIR score (r = -0.19; p < 0.001, and CAP (r = -0.15; p < 0.01).
UNASSIGNED: In subjects with a BMI ≥ 28 kg/m2, liver fat fraction is significantly elevated in those with T2DM compared to IGT or NGT. Liver fat fraction is associated with deteriorating insulin sensitivity and loss of glucose control. Despite a continuous increase in insulin resistance, no change in liver fat content or stiffness occurred over 30 months.
UNASSIGNED: Insulin resistance, glucose control and several parameters for liver integrity were monitored in 177 overweight (BMI > 28 kg/m2) subjects over a mean of 30 months. Volunteers were categorized according to insulin resistance (HOMAIR score) and glucose control in subjects with normal glucose control (NGT), impaired glucose control (IGT), or diabetes mellitus type 2 (T2DM). Liver fat and fibrosis were evaluated by sonographic elastography (FibroScan®) and clinical scores, such as the AST/ALT ratio, fatty liver index (FLI), and NAFLD fibrosis score (NFS).
UNASSIGNED: Liver fat fraction as estimated by the controlled attenuation parameter (CAP), and the FLI were significantly higher in subjects with T2DM compared to IGT and NGT. While fasting insulin levels and the HOMAIR score continuously increased over time, no change in CAP or FLI occurred during follow up. CAP was correlated with FLI (r = 0.50; p < 0.0001) and the HOMAIR score (r = 0.32; p < 0.0001). An inverse correlation was observed between serum adiponectin levels and FLI (r = -0.37; p < 0.0001), the HOMAIR score (r = -0.19; p < 0.001, and CAP (r = -0.15; p < 0.01).
UNASSIGNED: In subjects with a BMI ≥ 28 kg/m2, liver fat fraction is significantly elevated in those with T2DM compared to IGT or NGT. Liver fat fraction is associated with deteriorating insulin sensitivity and loss of glucose control. Despite a continuous increase in insulin resistance, no change in liver fat content or stiffness occurred over 30 months.
摘要：
■这项观察性试验是为了评估超重或肥胖受试者在胰岛素抵抗和血糖控制方面随时间变化的肝脏参数。
■胰岛素抵抗，在平均30个月的时间内,对177名超重(BMI>28kg/m2)受试者的血糖控制和几个肝脏完整性参数进行了监测.根据胰岛素抵抗（HOMAIR评分）和血糖控制正常（NGT）受试者的血糖控制对志愿者进行分类。血糖控制受损（IGT），或2型糖尿病（T2DM）。通过超声弹性成像（FibroScan®）和临床评分评估肝脏脂肪和纤维化，例如AST/ALT比率，脂肪肝指数（FLI），和NAFLD纤维化评分（NFS）。
■通过受控衰减参数（CAP）估计的肝脏脂肪分数，与IGT和NGT相比，T2DM受试者的FLI明显更高。虽然空腹胰岛素水平和HOMAIR评分随着时间的推移而不断增加，随访期间CAP或FLI无变化.CAP与FLI(r=0.50;p<0.0001)和HOMAIR评分(r=0.32;p<0.0001)相关。血清脂联素水平与FLI呈负相关(r=-0.37;p<0.0001),HOMAIR评分(r=-0.19;p<0.001,CAP评分(r=-0.15;p<0.01)。
■在BMI≥28kg/m2的受试者中，与IGT或NGT相比，T2DM患者的肝脏脂肪分数显着升高。肝脏脂肪分数与胰岛素敏感性下降和葡萄糖控制丧失有关。尽管胰岛素抵抗持续增加，30个月后肝脏脂肪含量或硬度无变化.
■胰岛素抵抗，在平均30个月的时间内,对177名超重(BMI>28kg/m2)受试者的血糖控制和几个肝脏完整性参数进行了监测.根据胰岛素抵抗（HOMAIR评分）和血糖控制正常（NGT）受试者的血糖控制对志愿者进行分类。血糖控制受损（IGT），或2型糖尿病（T2DM）。通过超声弹性成像（FibroScan®）和临床评分评估肝脏脂肪和纤维化，例如AST/ALT比率，脂肪肝指数（FLI），和NAFLD纤维化评分（NFS）。
■通过受控衰减参数（CAP）估计的肝脏脂肪分数，与IGT和NGT相比，T2DM受试者的FLI明显更高。虽然空腹胰岛素水平和HOMAIR评分随着时间的推移而不断增加，随访期间CAP或FLI无变化.CAP与FLI(r=0.50;p<0.0001)和HOMAIR评分(r=0.32;p<0.0001)相关。血清脂联素水平与FLI呈负相关(r=-0.37;p<0.0001),HOMAIR评分(r=-0.19;p<0.001,CAP评分(r=-0.15;p<0.01)。
■在BMI≥28kg/m2的受试者中，与IGT或NGT相比，T2DM患者的肝脏脂肪分数显着升高。肝脏脂肪分数与胰岛素敏感性下降和葡萄糖控制丧失有关。尽管胰岛素抵抗持续增加，30个月后肝脏脂肪含量或硬度无变化.
